Secarna Pharmaceuticals Expands AI-Powered Oligonucleotide Partnership with Curie.Bio
核心洞察
Secarna Pharmaceuticals (搜索) and Curie.Bio (搜索) have expanded their scientific and strategic collaboration agreement originally announced in May 2025, demonstrating the success of their initial partnership.
The expansion enables Secarna to support Curie.Bio (搜索) portfolio companies in identifying oligonucleotide candidates using its proprietary AI-empowered OligoCreator® (搜索) platform.
The partnership leverages Secarna's integrated platform that combines diverse delivery technologies with safety and efficacy testing systems to accelerate oligonucleotide therapeutic development.
Secarna Pharmaceuticals (搜索) GmbH & Co. KG announced on March 3, 2026, the expansion of its existing scientific and strategic collaboration agreement with Curie.Bio (搜索), originally established in May 2025. The expanded partnership will enable Secarna to support oligonucleotide candidate identification for research and development projects conducted by Curie.Bio's portfolio companies using its proprietary OligoCreator® (搜索) platform.
Strategic Partnership Validation
"The decision to expand our cooperation serves as validation of our fruitful partnership with Curie.Bio (搜索) so far," said Konstantin Petropoulos, PhD, CEO of Secarna Pharmaceuticals (搜索). "It shows a high level of trust between our teams who excellently work together to discover and develop new therapies against difficult to treat diseases. Our shared vision of transforming scientific innovation into life-changing therapies guides our daily work, driving us to efficiently generate measurable results in discovering and developing best-in-class drug products."
AI-Empowered Platform Technology
Secarna's OligoCreator® (搜索) platform represents a comprehensive approach to oligonucleotide therapeutic development, seamlessly integrating diverse delivery technologies with proprietary safety and efficacy testing systems. The AI-empowered platform is designed to identify and characterize oligonucleotide therapeutics (搜索) with exceptional speed, safety, and efficacy, positioning it as a pivotal tool in transforming previously untreatable conditions into treatable ones.
The platform's integrated approach enables targeted delivery of oligonucleotide therapies to specific cells, organs, or tissues where they are needed, potentially revolutionizing treatments for a wide range of difficult-to-treat disorders.
Venture Capital and Drug Development Integration
Curie.Bio (搜索) operates as a $1.25B global venture capital firm with a unique model that combines capital investment with hands-on drug development expertise. The firm functions as both a drug discovery copilot and investor, partnering with founders by investing in existing companies, creating focused spinouts, and building companies from scratch.
The firm's 100+ person team comprises experienced drug hunters, drug makers, and operators who work closely with founders on a day-to-day basis to improve decision-making and increase the probability of success. Curie.Bio (搜索)'s approach focuses on helping founders avoid critical early mistakes while ensuring they have the appropriate scientific plan, data package, and narrative to maximize long-term value creation.
Therapeutic Development Scope
The expanded collaboration targets the discovery and development of oligonucleotide therapeutics (搜索) for conditions that are beyond the reach of current approaches and modalities. Curie.Bio (搜索) invests across the complete lifecycle of therapeutic development, from preclinical discovery through clinical proof-of-concept, providing comprehensive support for drug development initiatives.
Secarna's platform technology aims to transform untreatable conditions into treatable ones, with the potential to profoundly shape the future of medicine through targeted oligonucleotide therapies.